EMBARGOED FOR EARLY RELEASE: 11 A.M. (CT) MONDAY, NOVEMBER 5, 2012
Media Advisory: To contact corresponding author Dariush Mozaffarian, M.D., Dr.P.H., call Todd Datz at 617-432-8413 or email firstname.lastname@example.org. To contact corresponding author Roberto Marchioli, M.D., email email@example.com.
CHICAGO – Among patients undergoing cardiac surgery, supplementation with a n-3-polyunsaturated fatty acid (fish oil) before and after surgery did not reduce the risk of postoperative atrial fibrillation, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the American Heart Association’s Scientific Sessions.
“Postoperative atrial fibrillation or flutter (AF) occurs in approximately 1 of 3 patients undergoing cardiac surgery, and rates of this complication remain unchanged, even with advances in surgical techniques, anesthetic procedures, and perioperative care,” according to background information in the article. Postoperative AF can cause symptoms requiring escalation of supportive therapies and renal and neurological complications. The authors note that “new therapies are needed to prevent postoperative AF and its associated morbidity and health care costs.”
“Experimental evidence supports direct and indirect antiarrhythmic effects of long-chain n-3 polyunsaturated fatty acids (n-3-PUFAs) in fish oil, especially in the setting of acute ischemia. Yet effects of n-3-PUFAs on atrial arrhythmias such as postoperative AF remain uncertain.”
Dariush Mozaffarian, M.D., Dr.P.H., of the Harvard School of Public Health, Boston, and colleagues conducted a study to determine whether perioperative administration of oral n-3-PUFAs reduces postoperative AF in patients undergoing cardiac surgery. The study (Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation [OPERA]) was a randomized, placebo-controlled, multinational, clinical trial that included a total of 1,516 patients who were scheduled for cardiac surgery in the United States, Italy, and Argentina. Patients were enrolled between August 2010 and June 2012 and were randomized to receive fish oil (1-gram capsules containing 840 mg or more of n-3- PUFA as ethyl esters) or placebo, with preoperative loading of 10 grams over 3 to 5 days (or 8 grams over 2 days) followed postoperatively by 2 grams/day until hospital discharge or postoperative day 10, whichever came first.
At the beginning of the study, the average age of the patients was 64 years; 1,094 patients (72.2 percent) were men, and cardiovascular risk factors were common. Fifty-two percent of patients had planned valvular surgery.
The researchers found that the primary end point (occurrence of postoperative AF lasting longer than 30 seconds) occurred in 233 patients (30.7 percent) in the placebo group and 227 (30.0 percent) in the n-3-PUFA group. “None of the secondary end points were significantly different between the placebo and fish oil groups, including postoperative AF that was sustained, symptomatic, or treated (231 [30.5 percent] vs. 224 [29.6 percent]) or number of postoperative AF episodes per patient (1 episode: 156 [20.6 percent] vs. 157 [20.7 percent]; 2 episodes: 59 [7.8 percent] vs. 49 [6.5 percent]; ≥3 episodes: 18 [2.4 percent] vs. 21 [2.8 percent]).”
The total number of days in the intensive care unit or coronary care unit, of telemetry monitoring, or of total hospital stay did not differ significantly between groups. Also, supplementation with n-3-PUFAs was generally well-tolerated, with no evidence for increased risk of bleeding or serious adverse events.
“This large, multinational, double-blind, placebo-controlled clinical trial found no evidence that perioperative n-3-PUFA supplementation reduced postoperative AF. Results were similar for various secondary end points, among different patient subgroups, and in various sensitivity analyses. Major strengths of OPERA include its large size and large numbers of events, which achieved anticipated statistical power. Our broad inclusion criteria and multinational enrollment support the generalizability of our findings,” the researchers conclude.
(doi:10.1001/jama. 2012.28733;. Available pre-embargo to the media at http://media.jamanetwork.com)
Editor’s Note: The OPERA trial was an investigator-initiated, not-for-profit trial sponsored by the OPERA Investigators, who had full responsibility for study planning and conduct, curation of the study database, and discretion on data utilization, analysis, and publication. Financial support was provided by the National Heart, Lung, and Blood Institute, National Institutes of Health, GlaxoSmithKline, Sigma Tau, and Pronova BioPharma, which also provided the study drug. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
# # #